Business Wire

Galderma Launches Transformative Skincare Segment With Cetaphil’s New Skin Activator Hydrating & Firming Line, in Partnership With Actor and Filmmaker Mariska Hargitay

18.9.2025 08:00:00 EEST | Business Wire | Press release

Share

Galderma today announced Cetaphil, the dermatologist-recommended brand trusted by millions with sensitive skin, is redefining daily skincare with its new Skin Activator Hydrating & Firming line. The launch marks an entirely new skincare segment of advanced hydration and firming solutions designed specifically for improving the appearance of aging, thinning, and fragile skin. As people age, surface skin cells stop performing at the same level, or “go to sleep,” causing fine lines, dehydration, and looser skin, in turn leading to skin looking and feeling less firm and more fragile.1

Skin Activator technology serves as a “wake-up call” to sleeping surface skin cells. The unique complex is powered by encapsulated CICA to help restore the skin’s moisture barrier to visibly plump and firm skin as well as microdosed mandelic acid to increase surface skin cell turnover to visibly reduce dull, uneven skin. In clinical trials, the Skin Activator Hydrating & Firming Lotion showed to be effective in improving the appearance of skin crepiness and smooth skin’s texture in one week. It was also proven to hydrate for firmer-looking skin in just four weeks. Moreover, when patients were asked about their experiences, 88% of Skin Activator Hydrating & Firming Cream users said their skin looked less crepey in 2 days, and 87% said their skin appeared more youthful after one week.2

“This launch signals a turning point in how we approach skin longevity. It’s more fundamental than wrinkles or loss of firmness, it’s about preserving surface skin health at the cellular level. As skin undergoes changes with age, it demands more precise, science-driven support. This insight fueled the development of our Skin Activator Hydrating & Firming line: a dermatologist-developed routine designed to strengthen, revitalize, and transform skin’s appearance.”

ALAN D. WIDGEROW, MBBCH, MMED, FCS, FACS
CHIEF SCIENTIFIC OFFICER GALDERMA
HEAD OF INNOVATION, DERMATOLOGICAL SKINCARE

In developing the Skin Activator Hydrating & Firming Line, Galderma partnered with a medical advisory board of leading dermatologists.

“As a dermatologist, I’m always looking for what’s next in skin science, especially when it comes to aging. That’s why I was so excited to work with Cetaphil on the Skin Activator Hydrating & Firming line. We took on one of the biggest underlying causes of visible aging: surface skin health and cell senescence. By targeting these ‘zombie cells,’ we’re helping to support skin renewal in a way that’s truly backed by science. It’s been incredibly rewarding to help bring that kind of innovation to a skincare routine patients can use all over, every day.”

DR. GLYNIS ABLON*
BOARD-CERTIFIED DERMATOLOGIST
ASSOCIATE CLINICAL PROFESSOR, UNIVERSITY OF CALIFORNIA, LOS ANGELES

A new era of skin activation, backed by science and brought to life by a cultural icon
To help bring this segment-defining line to life, Cetaphil is proud to partner with acclaimed actress, director, and advocate, Mariska Hargitay. Known for her strength, compassion, and authenticity, Hargitay represents a powerful voice in embracing beauty at every stage of life. As the face of the campaign, she will help share a message of empowerment and reinvention – giving women the tools to reawaken both their skin’s look and their aspirations. Hargitay’s partnership will span across a robust marketing effort, inclusive of PR, advertising, in-store, retailer e-commerce, and social.

Fragrance-free, non-comedogenic, and hypoallergenic, the Skin Activator Hydrating & Firming line also embraces the trending notion of “skinification,” or using facial care-inspired ingredients to address full-body skincare needs. Products within the newly launched Skin Activator Hydrating & Firming Line include:

  • Cetaphil Hydrating & Firming Cream for Neck, Chest, and Face (3.4 oz.)
  • Cetaphil Hydrating & Firming Cream for Body (12 oz.)
  • Cetaphil Hydrating & Firming Lotion (16 oz.)

The Hydrating & Firming Line is now widely available for purchase in the United States. Galderma is working to bring this new innovation to other international markets where Cetaphil is already available. See full list of retailers here: https://www.cetaphil.com/us/where-buy. For more information, consumers can also follow Cetaphil on Instagram (@Cetaphil) and TikTok (@Cetaphil) or visit www.cetaphil.com.

About Cetaphil®
Over seventy-five years ago, a leading pharmacist created the first Cetaphil product – a gentle, yet powerful formula that would clean without stripping and moisturize without clogging. Today, Cetaphil is a dermatologist recommended sensitive skincare brand and is recognized around the world. With the help of leading global skincare experts, they continue to develop innovative skincare technologies for sensitive skin that help restore, protect and maintain skin's health every day. For more information, visit www.cetaphil.com.

About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermato-logical Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.

References and disclaimers:

  1. Novel Strategy for Strengthening Dermatoporotic Skin by Managing Cellular Senescence. J Drugs Dermatol. 2024 Sep 1;23(9):748-756. doi: 10.36849/JDD.8388.
  2. Galderma 12-week in-use study-consumer data questionnaire. Subject data on file.

* Paid Galderma Consultant; Galderma Clinical Study investigator for the Cetaphil hydrating & firming product line

View source version on businesswire.com: https://www.businesswire.com/news/home/20250917102132/en/

Contacts

Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50

Jeffrey Smith
Head of U.S. Communications
jeffrey.smith@galderma.com
+ 1 (682) 401-8428

Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12

Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Philip Morris International Publishes Inaugural Taskforce on Nature-related Financial Disclosures Report22.9.2026 12:00:00 EEST | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today published its inaugural Taskforce on Nature-related Financial Disclosures (TNFD) Report, providing shareholders and other stakeholders with its most comprehensive assessment to date of nature-related dependencies, impacts, risks, and opportunities (DIROs) across the company’s global value chain. As an early adopter of the TNFD recommendations, PMI’s TNFD Report supports the company’s efforts to sharpen its understanding of how natural capital considerations influence business resilience and decision-making over time, while contributing to emerging practices in nature-related disclosure. Nature is one of the six strategic priorities that define PMI’s Value Plan 2030+, the company’s framework for long-term sustainable value creation, alongside Consumers, Circularity, Climate, Our Workforce, Workers in Our Value Chain. The TNFD Report follows the release of PMI’s 2025 Climate Transition Plan, prepared in line with the TCFD framework,

ROSHN Group Expands Foreign Real Estate Ownership Opportunities Across Saudi Arabia22.9.2026 10:00:00 EEST | Press release

ROSHN Group, Saudi Arabia’s leading master developer and a PIF company, is supporting a new chapter for international participation in the Saudi real estate market, as the Kingdom’s regulations governing non-Saudi property ownership create new opportunities for eligible international buyers and investors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260922356820/en/ ROSHN Group offers world-class living and investment opportunities, including SEDRA Curated Collection in Riyadh (Photo: AETOSWire) Thousands of non-Saudi buyers have registered interest with ROSHN Group since the regulatory updates, reflecting the growth and diversification of the Kingdom’s real estate sector by attracting new sources of demand and investment, while complementing the continued delivery of homes and communities for Saudi citizens. For ROSHN Group, this creates an opportunity to broaden access to its growing portfolio while expanding housing sup

Regnology Research Maps Route From AI Pilots to Production in Regulatory Reporting22.9.2026 09:33:00 EEST | Press release

Regnology, a leader in regulatory, risk, tax and finance reporting technology, today published “The Agentic Gap: From Control to Intelligence in Regulatory Reporting”, accompanied by a video foreword from Chief Executive Officer Rob Mackay. The global study sets out where agentic AI can take on meaningful operational load today, and gives institutions a practical roadmap from isolated pilots into scaled production. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921218912/en/ The research finds an industry already mobilizing. 87% of respondents are exploring, piloting or embedding AI in operations, and only 13% report no current plan. The constraint is a shared one. Embedded, production-level use sits between 8% and 15% at every institution tier, and 16% of respondents overall have reached it, with 89% of financial institutions yet to get there. Resources buy experimentation, but production use is earned on the same terms

Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 2028 1 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 08:30:00 EEST | Press release

Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements: Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio

OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 08:00:00 EEST | Press release

OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of 96% over each program’s original media combinations*. In separate internal studies, OPM-CHO media demonstrated lot-to-lot variability below 5%.* As patent expirations create new opportunities for biosimilar development, achieving a pr

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye